Description
SLU-PP-332 | ERRalpha/gamma Agonist — Research Grade
SLU-PP-332 is a synthetic small molecule developed at Saint Louis University that activates Estrogen-Related Receptors alpha and gamma (ERRalpha/ERRgamma) — orphan nuclear receptors that act as master regulators of mitochondrial energy metabolism and oxidative fibre gene expression in skeletal muscle.
Mechanism of Action
- ERRalpha/ERRgamma agonism — activates ERR nuclear receptors that drive transcription of PGC-1alpha-target genes governing mitochondrial biogenesis
- Oxidative fibre switching — promotes type I (slow-twitch, oxidative) fibre gene expression in skeletal muscle
- Mitochondrial biogenesis — increases mitochondrial content, OXPHOS capacity, and fatty acid oxidation gene expression
- Endurance enhancement — preclinical rodent data: 70% increase in treadmill running duration without exercise training
Research Areas
SLU-PP-332 is studied in exercise physiology, metabolic disease (obesity, diabetes), heart failure (cardiac oxidative metabolism), and sarcopenia. It represents a pharmacological approach to ERR-mediated exercise adaptation, distinct from AMPK-based compounds.
For Research Use Only. Rainbow Peptide supplies SLU-PP-332 exclusively for in vitro and laboratory research purposes. Not for human or veterinary use.
Dr. T. Bhardwaj –
SLU-PP-332 for our ERRα/ERRγ pan-agonist and mitochondrial biogenesis research. Purity confirmed >99% by our HPLC. Nuclear receptor coactivation assay showed the expected potency profile. COA excellent and traceable.
A. Svensson –
SLU-PP-332 is a novel compound and hard to source at high purity. Rainbow Peptide delivered >99% confirmed by LC-MS. Our exercise mimetic model showed expected mitochondrial pathway activation. Outstanding quality.
L. Osei –
SLU-PP-332 performed well in our ERR agonist panel. Purity >98.5%. Dissolved in DMSO cleanly. COA detailed. Our mitochondrial gene expression assay showed dose-dependent response. Will continue ordering.